Comparative Pharmacology
Head-to-head clinical analysis: SULFAPYRIDINE versus SULSOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAPYRIDINE versus SULSOXIN.
SULFAPYRIDINE vs SULSOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfapyridine is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production. It also has anti-inflammatory and immunomodulatory effects in dermatologic conditions through unknown mechanisms.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
500 mg orally four times daily for initial treatment of dermatitis herpetiformis; maintenance dose 500 mg daily to 1.5 g daily in divided doses.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
None Documented
None Documented
Clinical Note
moderateSulfapyridine + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfapyridine is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Sulfapyridine
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfapyridine."
Terminal elimination half-life: 6–10 hours (prolonged in renal impairment or slow acetylators); clinical context: requires dosing adjustment in renal insufficiency.
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Renal: approximately 70–80% (30% as unchanged drug, remainder as metabolites, primarily N4-acetylsulfapyridine); biliary/fecal: minor (<5%).
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic